Literature DB >> 2150814

In vitro antimicrobial activity of imipenem in combination with vancomycin or teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis.

J G Barr1, E T Smyth, G M Hogg.   

Abstract

The interaction between imipenem and two glycopeptides against staphylococci was examined for potential synergy. Imipenem in combination with vancomycin or teicoplanin exerted a synergistic or additive effect against a majority of Staphylococcus aureus and Staphylococcus epidermidis isolates tested by the checkerboard method. Synergistic inhibitory effects were frequently accompanied by synergistic bactericidal effects. For a proportion of bacterial isolates of both species, the demonstration of synergy by the checkerboard method was confirmed by time-kill studies using antibiotic combinations at the MICs or at achievable serum antibiotic levels. Only with a single isolate of Staphylococcus epidermidis was antagonism with either antibiotic combination recorded.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2150814     DOI: 10.1007/bf01967378

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  The estimation of the bactericidal power of the blood.

Authors:  A A Miles; S S Misra; J O Irwin
Journal:  J Hyg (Lond)       Date:  1938-11

2.  Interaction of teicoplanin with other antimicrobial agents against gram-positive aerobes.

Authors:  B Watt
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

3.  In-vitro teicoplanin-resistance in coagulase-negative staphylococci from patients with endocarditis and from a cardiac surgery unit.

Authors:  E P Moore; D C Speller
Journal:  J Antimicrob Chemother       Date:  1988-04       Impact factor: 5.790

4.  In-vitro studies of antibiotic combinations for multiply-resistant coagulase-negative staphylococci.

Authors:  R A Proctor; P Wick; R J Hamill; P Horstmeier; J Gullings-Handley; M Weisensel; G Brandt
Journal:  J Antimicrob Chemother       Date:  1987-08       Impact factor: 5.790

5.  In vitro interactions between teicoplanin and other antibiotics against enterococci and staphylococci.

Authors:  E Debbia; A Pesce; G C Schito
Journal:  J Hosp Infect       Date:  1986-03       Impact factor: 3.926

6.  Changing resistance to antimicrobial drugs, and resistance typing in clinically significant strains of Staphylococcus epidermidis.

Authors:  J F Richardson; R R Marples
Journal:  J Med Microbiol       Date:  1982-11       Impact factor: 2.472

7.  In-vitro antimicrobial activity of enoxacin in combination with eight other antibiotics against Pseudomonas aeruginosa, Enterobacteriaceae and Staphylococcus aureus.

Authors:  A L Baltch; C Bassey; G Fanciullo; R P Smith
Journal:  J Antimicrob Chemother       Date:  1987-01       Impact factor: 5.790

8.  Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients.

Authors:  J Klastersky; M P Glauser; S C Schimpff; S H Zinner; H Gaya
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

9.  Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapy.

Authors:  J P Sculier; D Weerts; J Klastersky
Journal:  Eur J Cancer Clin Oncol       Date:  1984-01

10.  Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria.

Authors:  Y Glupczynski; H Lagast; P Van der Auwera; J P Thys; F Crokaert; E Yourassowsky; F Meunier-Carpentier; J Klastersky; J P Kains; E Serruys-Schoutens
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

View more
  10 in total

1.  Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin.

Authors:  M W Climo; R L Patron; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

2.  Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin.

Authors:  N Aritaka; H Hanaki; L Cui; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

3.  Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.

Authors:  Jeffrey Fernandez; Darren Abbanat; Wenchi Shang; Wenping He; Karen Amsler; James Hastings; Anne Marie Queenan; John L Melton; Alfred M Barron; Robert K Flamm; A Simon Lynch
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

4.  In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains.

Authors:  S Rochon-Edouard; M Pestel-Caron; J F Lemeland; F Caron
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

5.  Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response.

Authors:  B H Ackerman; A M Vannier; E B Eudy
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

Review 6.  Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

7.  Interactions between glycopeptides and beta-lactams against isogenic pairs of teicoplanin-susceptible and -resistant strains of Staphylococcus haemolyticus.

Authors:  Carla Vignaroli; Francesca Biavasco; Pietro E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

8.  β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA.

Authors:  Nikki Tran; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.938

9.  In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections.

Authors:  Lorenzo Drago; Elena De Vecchi; Lucia Nicola; Maria Rita Gismondo
Journal:  BMC Infect Dis       Date:  2007-09-21       Impact factor: 3.090

10.  In Vitro activity of novel glycopolymer against clinical isolates of multidrug-resistant Staphylococcus aureus.

Authors:  Vidya P Narayanaswamy; Scott A Giatpaiboon; John Uhrig; Paul Orwin; William Wiesmann; Shenda M Baker; Stacy M Townsend
Journal:  PLoS One       Date:  2018-01-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.